OCT 08, 2019 3:03 PM PDT

Using temperature to awaken immune response to fight brain cancer

Glioblastoma is the most common form of adult brain cancer and also one of the most aggressive human cancers. Immunotherapy has yet to be shown proven effective against glioblastomas, and the length of survival for patients with the tumors following aggressive surgical resection, chemotherapy, and radiation therapy is still only fourteen months. About 14,000 people are diagnosed with the disease every year.

The dreary reality of this diagnosis is what makes new research published in Advanced Therapeutics so hopeful. As the collaborating authors of the study explain, their research details a technique that aims to take advantage of temperature in order to, “induce accumulation of requisite immune cells in the glioblastoma microenvironment, thereby transforming a “cold” to a “hot” immune microenvironment.”

 

"Our body has armies of white blood cells that help us fight off bacteria, viruses, and cancer cells. This constellation of cells constitutes our immune system," comments senior author Clark C. Chen, MD, Ph.D., Lyle French Chair in Neurosurgery and Head of the Department of Neurosurgery at the University of Minnesota Medical School. "One of the key reasons why glioblastoma is so aggressive is that it shuts off this immune system.”

And that’s also why glioblastomas don’t respond to immunotherapy. "Immunotherapy works by activating the white blood cells that are present in many cancer types. For reasons that are not clear, glioblastomas contain few white blood cells. So, there is nothing for immunotherapy to activate," adds co-senior author Andrew Kummel, Professor of Chemistry and Biochemistry at the University of California San Diego.

But let’s go back a moment. What exactly does a “cold” or “hot” immune microenvironment refer to? Previous studies have shown that glioblastomas produce a “cold” microenvironment, meaning one that is lacking the substrate immune cells that would be necessary for immunotherapy to be effective. Hence, the scientists had the idea that by manipulating the temperature of the immune microenvironment of a tumor, they could potentially activate more immune cells, making the tumor more susceptible to immunotherapy. They call this temperature manipulation the Goldilocks effect, referring to the story of the young girl who tastes three different bowls of porridge, one too hot, one too cold, and one just right.

Roughly 14,000 people are diagnosed with glioblastoma every year; it is one of the most agressive cancer tumors. Photo: Pixabay

This discovery was unexpected even to the researchers, says Chen. "Impressively, immunotherapy works only when the ultrasound is adjusted to maintain a stable body temperature as the cancer cells are ruptured," muses Chen. "Temperatures that deviate too much from the body temperature appear to compromise the effectiveness of the white blood cells. This 'Goldilocks' aspect of immunotherapy was not previously appreciated."

Already the team has collaborated with Professor of Electrical and Computer Engineering, Emad Ebbini, to develop an ultrasound system that is able to manipulate the tumors’ microenvironment based on the findings. Ebbini comments, "Our ultrasound is a perfect fit for the type of clinical application that Dr. Chen has developed. We are working toward a first-in-human study to test our ultrasound in glioblastoma patients."

Sources: Advanced Therapeutics, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUN 10, 2020
Drug Discovery & Development
A Highly Targeted Cancer Therapeutic
JUN 10, 2020
A Highly Targeted Cancer Therapeutic
A study led by researchers at USC School of Pharmacy discusses a way to engineer drugs that highly target malignant tiss ...
JUL 11, 2020
Cancer
New drug combo could improve immunotherapy for SCCOHT ovarian cancer
JUL 11, 2020
New drug combo could improve immunotherapy for SCCOHT ovarian cancer
Research published recently in PLOS ONE reports on SP-2577, a drug that could help girls and young women plagued with a ...
JUL 18, 2020
Cancer
Clinical trials go forth for osteosarcoma in dogs and glioblastoma multiforme in humans using the same precision medicine
JUL 18, 2020
Clinical trials go forth for osteosarcoma in dogs and glioblastoma multiforme in humans using the same precision medicine
A development in precision medicine in cancer treatment for dogs has led to a similar advancement in cancer treatment fo ...
JUL 19, 2020
Drug Discovery & Development
Nanodrug for Treating Invasive Breast Cancer
JUL 19, 2020
Nanodrug for Treating Invasive Breast Cancer
Scientists at the University of Arkansas created a nano-drug that may eradicate triple-negative breast cancer cells. Fin ...
JUL 22, 2020
Cancer
Immunotherapy: the risk for cancer patients with COVID-19
JUL 22, 2020
Immunotherapy: the risk for cancer patients with COVID-19
Research presented at the American Association for Cancer Research Virtual Meeting: COVID-19 and Cancer earlier this wee ...
JUL 27, 2020
Genetics & Genomics
Pediatric Cancer Mutations Show the Importance of Non-Coding Regions
JUL 27, 2020
Pediatric Cancer Mutations Show the Importance of Non-Coding Regions
A new computational tool was created by scientists at CHOP and it has now revealed new mutations that are linked to five ...
Loading Comments...